Vanda Pharmaceuticals Inc (VNDA):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Vanda Pharmaceuticals Inc (VNDA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9809
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:36
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Vanda Pharmaceuticals Inc (Vanda Pharmaceuticals) is a specialty pharmaceutical company that develops and commercializesnovel therapies for the treatment of central nervous system disorders. The company’s products include Hetlioz, a melatonin receptor agonist for the treatment of non-24-hour sleep-wake disorder; and Fanapt, an atypical antipsychotic for the treatment of schizophrenia in adults. Its pipeline portfolio includes Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist for pruritus in atopic dermatitis; VQW-765 (formerly AQW-051), an alpha-7 nicotinic acetylcholine receptor for CNS disorders; and VTR-297 (formerly Trichostatin A) for oncology indications. Vanda Pharmaceuticals is headquartered in Washington DC, the US.

Vanda Pharmaceuticals Inc (VNDA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
Vanda Pharma Enters into Licensing Agreement with UC San Francisco 10
Novartis Pharma Enters into Licensing Agreement with Vanda Pharma for AQW-051 11
Vanda Pharma Enters Into Licensing Agreement With Eli Lilly For VLY-686 12
Equity Offering 13
Vanda Pharma Prices Public Offering of Shares for USD93.5 Million 13
Vanda Pharma Raises USD25 Million in Private Placement of Common Stock 15
Vanda Pharma Raises USD66.7 Million in Public Offering of Shares 17
Vanda Pharma Completes Public Offering Of Shares For US$52 Million 19
Acquisition 21
Vanda Pharma May Sell Itself 21
Vanda Pharmaceuticals Inc – Key Competitors 22
Vanda Pharmaceuticals Inc – Key Employees 23
Vanda Pharmaceuticals Inc – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Financial Announcements 25
Nov 07, 2018: Vanda Pharmaceuticals reports third quarter 2018 financial results 25
Aug 01, 2018: Vanda pharmaceuticals reports second quarter 2018 financial results 26
May 02, 2018: Vanda Pharmaceuticals Reports First Quarter 2018 Financial Results 27
Feb 14, 2018: Vanda Pharmaceuticals Reports Fourth Quarter 2017 Financial Results 28
Jan 07, 2018: Vanda Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2017 Revenue Results and 2018 Guidance 29
Nov 07, 2017: Vanda Pharmaceuticals Reports Third Quarter 2017 Financial Results 30
Aug 02, 2017: Vanda Pharmaceuticals Reports Second Quarter 2017 Financial Results 31
May 02, 2017: Vanda Pharmaceuticals Reports First Quarter 2017 Financial Results 32
Feb 15, 2017: Vanda Pharmaceuticals Reports Fourth Quarter 2016 and Full Year 2016 Financial Results 33
Jan 09, 2017: Vanda Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2016 Revenue Results and 2017 Financial Guidance 34
Legal and Regulatory 35
Nov 01, 2018: Vanda receives FDA letter regarding corporate webpage 35
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36

List of Tables
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vanda Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Vanda Pharma Enters into Licensing Agreement with UC San Francisco 10
Novartis Pharma Enters into Licensing Agreement with Vanda Pharma for AQW-051 11
Vanda Pharma Enters Into Licensing Agreement With Eli Lilly For VLY-686 12
Vanda Pharma Prices Public Offering of Shares for USD93.5 Million 13
Vanda Pharma Raises USD25 Million in Private Placement of Common Stock 15
Vanda Pharma Raises USD66.7 Million in Public Offering of Shares 17
Vanda Pharma Completes Public Offering Of Shares For US$52 Million 19
Vanda Pharma May Sell Itself 21
Vanda Pharmaceuticals Inc, Key Competitors 22
Vanda Pharmaceuticals Inc, Key Employees 23
Vanda Pharmaceuticals Inc, Subsidiaries 24

List of Figures
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Vanda Pharmaceuticals Inc (VNDA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Poudre Valley Rural Electric Association Inc:企業の戦略的SWOT分析
    Poudre Valley Rural Electric Association Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors …
  • Tactical Missiles Corporation:企業の戦略・SWOT・財務情報
    Tactical Missiles Corporation - Strategy, SWOT and Corporate Finance Report Summary Tactical Missiles Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • REC Silicon ASA (REC)-エネルギー分野:企業M&A・提携分析
    Summary REC Silicon ASA (REC Silicon), formerly Renewable Energy Corporation ASA, produces and supplies advanced silicon materials. It offers solar grade polysilicon, electronic grade polysilicon, and silicon gases. Its products find application in the solar and electronics industries in the product …
  • Sbarro, LLC:企業の戦略・SWOT・財務情報
    Sbarro, LLC - Strategy, SWOT and Corporate Finance Report Summary Sbarro, LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Natsionalna Elektricheska Kompania EAD:企業の戦略的SWOT分析
    Natsionalna Elektricheska Kompania EAD - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and ma …
  • Bashneft (BANE)-石油・ガス分野:企業M&A・提携分析
    Summary Bashneft is a vertically integrated oil and gas company. It operates in the oil and gas production, refining, petrochemical production, marketing and distribution of oil and petroleum products. It sales crude oil, petroleum products and petrochemical products to the domestic market. The comp …
  • NetSuite Inc:企業の戦略的SWOT分析
    NetSuite Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Sonic Healthcare Limited:企業のM&A・事業提携・投資動向
    Sonic Healthcare Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Sonic Healthcare Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • DSK Bank EAD :企業の戦略・SWOT・財務情報
    DSK Bank EAD - Strategy, SWOT and Corporate Finance Report Summary DSK Bank EAD - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Enercon GmbH:電力:M&Aディール及び事業提携情報
    Summary Enercon GmbH (Enercon) is a renewable energy equipment company that manufactures and supplies wind energy converters (WEC). It produces components of the WECs including annular generators, inverters, rotor blades, cast components, towers and machine houses. Enercon provides electrical and me …
  • AccorHotels:戦略・SWOT・企業財務分析
    AccorHotels - Strategy, SWOT and Corporate Finance Report Summary AccorHotels - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • NBN Co Ltd:企業の戦略的SWOT分析
    NBN Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • National Industrialization Co (2060):企業の財務・戦略的SWOT分析
    National Industrialization Co (2060) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Fraport Slovenija, d.o.o.:企業の戦略・SWOT・財務情報
    Fraport Slovenija, d.o.o. - Strategy, SWOT and Corporate Finance Report Summary Fraport Slovenija, d.o.o. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Cryptzone AB:企業の戦略的SWOT分析
    Cryptzone AB - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Women’s Choice Pharmaceuticals LLC-製薬・医療分野:企業M&A・提携分析
    Summary Women's Choice Pharmaceuticals LLC (WCP) is a pharmaceutical company that provides branded prescription products for women’s health care and urology markets. The company’s products include fem pH, a therapeutic vaginal jelly that is used to promote and maintain vaginal acidity caused by diab …
  • The McClatchy Company (MNI):企業の財務・戦略的SWOT分析
    The McClatchy Company (MNI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Nanosphere Inc-医療機器分野:企業M&A・提携分析
    Summary Nanosphere Inc (Nanosphere) a subsidiary of Cepheid is a medical device company that develops molecular diagnostic tests for disease detection and patient treatment. The company’s products comprise verigene system, instrumentation, bloodstream infection tests, gastrointestinal infection test …
  • Prudential Plc:戦略・SWOT・企業財務分析
    Prudential Plc - Strategy, SWOT and Corporate Finance Report Summary Prudential Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Glanbia Nutritionals Inc:企業の戦略的SWOT分析
    Glanbia Nutritionals Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆